Who Supplies Enalapril to India from BOTSWANA

To import finished pharmaceutical formulations containing Enalapril into India, the foreign manufacturer must obtain an Import Registration Certificate and an Import License from the Central Drugs Standard Control Organization (CDSCO). The application process involves submitting Form 41 for registration and Form 10 for the import license. The registration certificate is valid for three years from the date of issue. The application must include a Power of Attorney, Good Manufacturing Practice (GMP) certificate, Certificate of Pharmaceutical Product (COPP), Drug Master File (DMF), and sale or manufacturing license of the drug. The application process typically takes up to nine months from the date of receipt of the application.

Imported finished pharmaceutical formulations containing Enalapril are subject to quality testing by CDSCO-approved laboratories. The applicant must submit three consecutive batches for testing, providing adequate samples for reanalysis. Each batch must be accompanied by a Certificate of Analysis (CoA) tested in the export country’s laboratory, impurity standards, marker compounds, and reference standards along with their CoA. The testing ensures compliance with Indian Pharmacopoeia standards and ICH Zone IV stability data. Port inspection by customs drug inspectors is mandatory to verify the quality and authenticity of the imported formulations.

In April 2025, the Indian government introduced new regulations requiring import registration and licenses for all imported medicines, including finished formulations containing Enalapril. This measure aims to prevent the sale of unapproved or illegal medicines in the Indian market. The Central Drugs Standard Control Organization (CDSCO) emphasized that import registration and licenses are mandatory for importing drugs into India, as per the Drugs and Cosmetics Act and Rules.

India imports finished Enalapril formulations to meet the demand for antihypertensive treatments, particularly for patented or branded formulations and specific dosage forms not produced domestically. The domestic capacity may not fully satisfy the market needs, leading to reliance on imports. The market size for Enalapril formulations in India is substantial, with a total import value of $235.3 million across 261 exporters to 115 countries.

The Basic Customs Duty (BCD) for HS Code 30049071, which includes Enalapril formulations, is 10%. Additionally, a Social Welfare Surcharge (SWS) of 10% on the BCD is applicable. The Integrated Goods and Services Tax (IGST) is levied at 18% on the total of the assessable value plus BCD. There are no anti-dumping duties or exemptions for imports from Botswana. The total landed duty percentage is approximately 28.8%.

India sources finished Enalapril formulations from Botswana due to the availability of patented formulations, specialized dosage forms, and high-quality products. Botswana's share in India's total Enalapril formulation import market is minimal, with only one shipment valued at $2. Other major suppliers include China, Germany, and the United States, which collectively dominate the market. Botswana's competitive advantage lies in its ability to provide unique formulations and maintain high-quality standards.

India imports finished Enalapril formulations from Botswana due to the availability of unique formulations, specialized dosage forms, and high-quality products that may not be produced domestically. Botswana's adherence to international quality standards and its ability to supply patented formulations provide a strategic advantage for Indian buyers seeking to diversify their product offerings.

Compared to other major suppliers like China, Germany, and the United States, Botswana offers competitive pricing and high-quality products. While larger suppliers may offer lower prices due to economies of scale, Botswana's unique formulations and commitment to quality make it an attractive source for specific Enalapril formulations.

Importing finished Enalapril formulations from Botswana involves certain risks, including single-source dependency, currency fluctuations, regulatory changes, and potential shipping disruptions. To mitigate these risks, Indian importers should establish contingency plans, maintain buffer stocks, and stay informed about regulatory developments in both countries.

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), Documents Against Acceptance (DA), or Documents Against Payment (DP).
4. 4Minimum Order Quantities (MOQs): Clarify MOQs to optimize procurement costs.
5. 5Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and compliance with quality standards.

1. 1DGFT Importer Exporter Code (IEC): Obtain an IEC from the Directorate General of Foreign Trade.
2. 2CDSCO Form 41: Apply for the Import Registration Certificate.
3. 3CDSCO Form 10: Apply for the Import License.
4. 4Drug Master File (DMF): Prepare and submit a DMF for the product.
5. 5Certificate of Pharmaceutical Product (COPP): Obtain a COPP from the manufacturer.
6. 6Good Manufacturing Practice (